CYPHERPUNK TECHNOLOGIES INC. Warrants and Rights Outstanding
CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Warrants and Rights Outstanding of $3.45 million as of 2018-12-31, per its 10-K filed 2020-03-16.
Discontinued › Balance Sheet › Equity
us-gaap:WarrantsAndRightsOutstanding · last filed 2020-03-16
- 2018-12-31: Warrants and Rights Outstanding $3.45M.
- 2018-09-30: Warrants and Rights Outstanding $14.45M.
- 2018-06-30: Warrants and Rights Outstanding $16.25M.
- 2018-03-31: Warrants and Rights Outstanding $16.71M.
| Period end | Warrants and Rights Outstanding |
|---|---|
| 2018-12-31 | $3.45M 10-K · filed 2020-03-16 |
| 2018-09-30 | $14.45M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $16.25M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $16.71M 10-Q/A · filed 2018-08-08 |
| 2017-12-31 | $11.86M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |